Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABCZF OTCMKTS:ATTBF OTCMKTS:FFNTF OTCMKTS:MEOBF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZFAbcamC$22.25C$22.25C$5.00▼C$23.80N/AN/A2,659 shsN/AATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shsN/AFFNTF4Front Ventures$0.00$0.00▼$0.07N/AN/A1.28 million shs2,060 shsMEOBFMesoblast$1.70$1.67$0.96▼$2.59N/AN/A2,457 shsN/A7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZFAbcam0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%FFNTF4Front Ventures0.00%0.00%0.00%0.00%-50.00%MEOBFMesoblast0.00%0.00%0.00%+9.68%+17.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZFAbcamC$22.25C$22.25C$5.00▼C$23.80N/AN/A2,659 shsN/AATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shsN/AFFNTF4Front Ventures$0.00$0.00▼$0.07N/AN/A1.28 million shs2,060 shsMEOBFMesoblast$1.70$1.67$0.96▼$2.59N/AN/A2,457 shsN/A7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZFAbcam0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%FFNTF4Front Ventures0.00%0.00%0.00%0.00%-50.00%MEOBFMesoblast0.00%0.00%0.00%+9.68%+17.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCZFAbcam 0.00N/AN/AN/AATTBFAbattis Bioceuticals 0.00N/AN/AN/AFFNTF4Front Ventures 0.00N/AN/AN/AMEOBFMesoblast 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCZFAbcamN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AMEOBFMesoblastN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCZFAbcamN/AC$0.17130.73N/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/A-$0.16N/AN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AN/AN/AN/AMEOBFMesoblastN/A-$0.25N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABCZFAbcamC$0.070.32%N/A42.48%N/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AMEOBFMesoblastN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCZFAbcam43.58%ATTBFAbattis Bioceuticals32.45%FFNTF4Front VenturesN/AMEOBFMesoblast27.35%Insider OwnershipCompanyInsider OwnershipABCZFAbcamN/AATTBFAbattis BioceuticalsN/AFFNTF4Front VenturesN/AMEOBFMesoblastN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCZFAbcam1,750N/AN/ANot OptionableATTBFAbattis BioceuticalsN/AN/AN/ANot OptionableFFNTF4Front Ventures460N/AN/ANot OptionableMEOBFMesoblast80N/AN/ANot OptionableMEOBF, FFNTF, ATTBF, and ABCZF HeadlinesRecent News About These CompaniesCanaccord Genuity Remains a Buy on Mesoblast Limited (MEOBF)April 16, 2026 | theglobeandmail.comMesoblast hires Regeneron veteran to lead clinical development and medical affairsMarch 14, 2026 | theglobeandmail.comJEFFERIES Upgrades Mesoblast (MEOBF)January 29, 2026 | msn.comRyoncil® Net Revenues Increase for the Quarter to US$30MJanuary 29, 2026 | finance.yahoo.comMesoblast Limited (MEOBF) Receives a Buy from Canaccord GenuityDecember 19, 2025 | theglobeandmail.comHow Investors Are Reacting To Mesoblast (ASX:MSB) Remestemcel-L’s Remission Edge And FDA-Backed Niche LeadershipDecember 16, 2025 | finance.yahoo.comBELL POTTER SECURITIES Maintains Mesoblast (MEOBF) Buy RecommendationDecember 16, 2025 | msn.comMesoblast (MESO) Sees Optimism From AnalystsDecember 15, 2025 | msn.comGregory George Bought 40% More Shares In MesoblastSeptember 16, 2025 | finance.yahoo.comMesoblast Limited (MESO) Q4 2025 Earnings Call TranscriptAugust 29, 2025 | seekingalpha.comCanaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy RatingAugust 17, 2025 | finance.yahoo.comMesoblast Limited (MESO) Launches First Cell Therapy for ChildrenJuly 28, 2025 | finance.yahoo.comJPMorgan Chase & Co. Reduces Stake in Mesoblast LimitedJuly 24, 2025 | tipranks.comMesoblast Limited Announces Quotation of New Securities on ASXJuly 14, 2025 | tipranks.comMesoblast Limited Announces Cessation of SecuritiesJuly 14, 2025 | tipranks.comJPMorgan Acquires Substantial Stake in Mesoblast LimitedJuly 6, 2025 | tipranks.comMesoblast Aligns with FDA for Revascor Biologics License ApplicationJune 30, 2025 | tipranks.comJPMorgan Chase & Co. Reduces Stake in Mesoblast LimitedJune 25, 2025 | tipranks.comJPMorgan Chase & Co. Ceases to be Substantial Holder in Mesoblast LimitedJune 15, 2025 | tipranks.comMesoblast Advances FDA Approvals for Revascor® and Ryoncil®June 11, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMEOBF, FFNTF, ATTBF, and ABCZF Company DescriptionsAbcam OTCMKTS:ABCZFC$22.25 0.00 (0.00%) As of 06/5/2026Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.Abattis Bioceuticals OTCMKTS:ATTBFAbattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.4Front Ventures OTCMKTS:FFNTF4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.Mesoblast OTCMKTS:MEOBF$1.70 0.00 (0.00%) As of 06/5/2026Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
